Interplay between ShcA Signaling and PGC-1α Triggers Targetable Metabolic Vulnerabilities in Breast Cancer.

Area of Science:

• Oncology
• Molecular Biology
• Metabolism

Background:

• Receptor tyrosine kinases (RTKs) signal through adaptor proteins like ShcA.
• Aberrant RTK signaling drives oncogenesis in various cancers, including breast cancer.
• Metabolic reprogramming is a hallmark of cancer, supporting tumor growth and survival.

Purpose of the Study:

• To investigate the role of ShcA signaling in regulating breast cancer cell metabolism.
• To determine the impact of ShcA on glucose metabolism and mitochondrial function.
• To explore the therapeutic potential of targeting ShcA-mediated metabolic reprogramming.

Main Methods:

• Utilized mouse models of breast cancer (orthotopic and Polyoma virus middle T).
• Assessed metabolic parameters including glycolysis and oxidative phosphorylation.
• Investigated the role of PGC-1α in ShcA-driven metabolic changes.
• Evaluated the efficacy of biguanides (mitochondrial complex I inhibitors) in combination with ShcA inhibition.

Main Results:

• ShcA signaling enhances glucose metabolism via glycolysis and oxidative phosphorylation, increasing breast cancer cell dependence on glucose.
• ShcA induces PGC-1α, a key regulator of mitochondrial metabolism, crucial for tumor growth and initiation.
• Inhibition of ShcA signaling impairs metabolic rate and flexibility, sensitizing tumors to biguanides.
• Genetic ShcA inhibition delays tumor onset and growth in mouse models.

Conclusions:

• Metabolic reprogramming orchestrated by ShcA signaling is vital for breast cancer initiation and progression.
• A novel interplay between ShcA and PGC-1α coordinates metabolic adaptation in breast cancer.
• Targeting oxidative phosphorylation with biguanides represents a viable therapeutic strategy for ShcA-driven breast cancers.